Ocular PBM Research Library

Update: FDA Authorizes Photobiomodulation for Dry AMD

January 2025: The FDA has authorized light therapy (photobiomodulation) as the first non-invasive treatment for dry age-related macular degeneration. This regulatory milestone validates the growing body of research demonstrating red and near-infrared light's therapeutic potential for retinal health.

Read FDA Update from American Academy of Ophthalmology →
Browse Research by Category

Safe and effective: precise energy, clinical photobiomodulation light spectrum and timed dose are fundamental to the WaveFront’s vision support and macular health.

Primary, peer-reviewed research is at the core of WaveFront development. Below is our Research Library–the published, primary scientific resources we use to guide the design and output of the WaveFront. Our research is comprehensively updated as published studies become available, incorporated into our research & development and ultimately, our products.

We are pleased to make these resources available directly to you here–each is linked to its publication site and is summarised (Abstract) for your convenience.

To inspect the WaveFront’s output for safety and efficiency, find our WaveFront Evidence Alignment paper that synthesises key WaveFront energy and spectrum output with scientific studies in our Research Library.

Clinicians: we have prepared an ocular condition vs WaveFront output paper for your reference here

 

Vision Support & Macular Health

October 11, 2025

Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) , and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms.
wavefront

October 11, 2025

Shergill et al. (2024) reviewed IPL and light-based approaches for ocular rosacea, noting improvements in gland function and inflammatory control—mechanisms also engaged by PBM at 670 nm and 810 nm.

September 13, 2025

Photobiomodulation (PBM), also known as low-level laser therapy, is an emerging therapeutic modality in ophthalmology for its potential to manage a variety of ocular conditions. PBM employs low-energy light within the red and near-infrared spectrum. This interaction is believed to enhance mitochondrial function, boost adenosine triphosphate (ATP) production, and reduce oxidative stress, leading to improved cellular repair and tissue regeneration.
Vision Support & Macular Health

September 13, 2025

Red LED light with a wavelength of 600–700 nm enhances the immune response and cell proliferation, and NIR LED light with a wavelength 800 nm exerts anti-inflammatory effects. Several studies reported that PBM effectively improved the tear breakup time and tear volume and reduced the inflammatory response.

September 13, 2025

Low-level light therapy (PBM) treatment significantly improved signs and symptoms of dry eye in the early phases of treatment, suggesting its efficacy for dry eye management.
Vision Support & Macular Health

September 13, 2025

The use of LED-LLLT for the treatment of dry eye and MGD appears to be safe and beneficial.
Vision Support & Macular Health

September 13, 2025

670 nm PBM reduced central subfield thickness 42 μm and improved visual acuity in center-involved diabetic macular edema.
Vision Support & Macular Health

September 13, 2025

This pilot study aims to establish that treatment with near infrared light (NIR) reduces cystic macular oedema in patients with a retinal vein occlusion.
Vision Support & Macular Health

September 8, 2025

Over the past decade, more than 30 published studies have explored the value of PBM for ocular conditions.
Vision Support & Macular Health

September 8, 2025

In the past 20 years, experimental evidence has shown the benefit of PBM in increasing numbers of retinal and ophthalmic conditions. More recently, preclinical findings in ocular models have been translated to the clinic with promising results.
Load more